AbbVie (ABBV) Receives News Impact Rating of 0.21
Headlines about AbbVie (NYSE:ABBV) have trended somewhat positive on Thursday, Accern Sentiment reports. The research group scores the sentiment of media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. AbbVie earned a media sentiment score of 0.21 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 46.8627224920181 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
These are some of the news headlines that may have impacted Accern’s scoring:
- Beta Factor to Watch – AbbVie Inc., (NYSE: ABBV) – Stock Watch (stocksnewstimes.com)
- AbbVie’s (ABBV) “Hold” Rating Reiterated at BMO Capital Markets (americanbankingnews.com)
- Most Shocking Stock Movements: AbbVie Inc. (ABBV), Mylan NV (MYL) – Market Movers (financialqz.com)
- Technical Indicators in Focus: AbbVie Inc (NYSE: ABBV) – Alpha Beta Stock (alphabetastock.com)
- AbbVie (ABBV) Says Phase 3 MURANO Study of Venetoclax Chosen as Late-Breaking Abstract at ASH (streetinsider.com)
ABBV has been the topic of a number of research reports. Societe Generale raised their price target on shares of AbbVie in a research note on Tuesday. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $100.00 price target on shares of AbbVie in a research note on Friday, September 15th. SunTrust Banks, Inc. reaffirmed a “buy” rating and issued a $95.00 price target on shares of AbbVie in a research note on Wednesday, September 13th. Goldman Sachs Group, Inc. (The) reaffirmed a “buy” rating and issued a $100.00 price target (up from $85.00) on shares of AbbVie in a research note on Friday, September 8th. Finally, Jefferies Group LLC reaffirmed a “buy” rating and issued a $94.00 price target on shares of AbbVie in a research note on Friday, September 8th. Eight equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $94.68.
AbbVie (NYSE:ABBV) traded down $0.21 during mid-day trading on Thursday, reaching $94.47. 2,542,408 shares of the company’s stock were exchanged, compared to its average volume of 6,176,499. The firm has a market cap of $151,149.98, a P/E ratio of 17.83, a price-to-earnings-growth ratio of 1.31 and a beta of 1.51. The company has a debt-to-equity ratio of 5.08, a quick ratio of 1.32 and a current ratio of 1.45. AbbVie has a 12 month low of $58.60 and a 12 month high of $98.26.
AbbVie (NYSE:ABBV) last released its quarterly earnings data on Friday, October 27th. The company reported $1.41 EPS for the quarter, beating the Zacks’ consensus estimate of $1.39 by $0.02. The company had revenue of $7 billion during the quarter, compared to the consensus estimate of $7 billion. AbbVie had a net margin of 24.38% and a return on equity of 153.80%. AbbVie’s quarterly revenue was up 8.8% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.21 EPS. analysts anticipate that AbbVie will post 5.55 earnings per share for the current year.
The company also recently declared a quarterly dividend, which will be paid on Thursday, February 15th. Stockholders of record on Friday, January 12th will be issued a dividend of $0.71 per share. The ex-dividend date is Thursday, January 11th. This represents a $2.84 dividend on an annualized basis and a dividend yield of 3.01%. This is an increase from AbbVie’s previous quarterly dividend of $0.64. AbbVie’s dividend payout ratio (DPR) is currently 62.29%.
In other news, SVP Azita Saleki-Gerhardt sold 8,300 shares of the firm’s stock in a transaction that occurred on Monday, September 11th. The shares were sold at an average price of $85.02, for a total transaction of $705,666.00. Following the completion of the sale, the senior vice president now owns 93,099 shares in the company, valued at approximately $7,915,276.98. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Robert A. Michael sold 6,699 shares of the firm’s stock in a transaction that occurred on Thursday, September 28th. The stock was sold at an average price of $88.00, for a total transaction of $589,512.00. Following the sale, the vice president now owns 10,007 shares of the company’s stock, valued at approximately $880,616. The disclosure for this sale can be found here. Insiders have sold a total of 58,932 shares of company stock valued at $5,379,432 in the last 90 days. Insiders own 0.23% of the company’s stock.
WARNING: This article was first published by Watch List News and is the property of of Watch List News. If you are accessing this article on another website, it was illegally copied and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this article can be viewed at https://www.watchlistnews.com/abbvie-abbv-receives-news-impact-rating-of-0-21/1722389.html.
AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.
Receive News & Ratings for AbbVie Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.